Compound index

Growth Hormone Secretagogues & GHRH Analogs

Tesamorelin

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Overview

A modified GHRH analog in a specifically indicated FDA-approved medicine.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Egrifta SV / Egrifta WR · HIV-associated Lipodystrophy

    Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; not an indication for general weight management.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Evidence at a glance

Trials support a specific indication in adults with HIV-associated lipodystrophy; it is not approved for general weight management.

Key sources

Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.

Related compounds

  • CJC-1295

    Same target family · A 29-amino-acid chain. · Early human trials

  • Examorelin

    Same scientific class · A 6-amino-acid chain. · Early human trials

  • Ipamorelin

    Same scientific class · A 5-amino-acid chain. · Early human trials

  • Modified GRF (1–29)

    Same target family · A 29-amino-acid chain. · Cell/lab studies only

  • Pralmorelin

    Same scientific class · A 6-amino-acid chain. · Early human trials

Related glossary terms